Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Front Immunol ; 11: 919, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32670261

RESUMO

Donor-specific antibodies (DSAs) are the main risk factor for antibody-mediated rejection (ABMR) and graft loss but could have variable pathogenicity according to their IgG subclass composition. Luminex-based test might lack sensitivity for the detection of IgG subclasses and this test does not allow quantifying the relative abundance of each IgG subclass. We investigated the precise repartition of each DSA subclass and their role in ABMR occurrence and severity, using an innovative mass spectrometry-based method. Between 2014 and 2018, we enrolled 69 patients who developed de novo DSA (n = 29 without ABMR, and n = 40 with ABMR) in two transplant centers. All IgG subclasses were detected in every samples tested: 62.7% were IgG1, 26.6% were IgG2, 6.6% were IgG3, and 4.2% were IgG4. The IgG3 proportion was significantly higher in the ABMR+ compared to the ABMR- group (8.4% vs. 5.6%, p = 0.003). The proportion of IgG1, IgG2, and IgG4 of DSA was similar between the two groups. Higher IgG3 level was associated with higher C4d deposition, higher microvascular inflammation scores, and glomerular filtration rate decline >25%. IgG3 proportion was not correlated with DSA MFI. Multivariate analysis showed that proteinuria and high level of IgG3 DSA were the only two factors independently associated with ABMR. In conclusion, de novo DSA are always composed of the four IgG subclasses, but in different proportions. High IgG3 proportion is associated with ABMR occurrence and severity and with poorer outcome, independently of DSA MFI.


Assuntos
Rejeição de Enxerto/imunologia , Imunoglobulina G/imunologia , Isoanticorpos/imunologia , Transplante de Rim/efeitos adversos , Espectrometria de Massas em Tandem , Adulto , Idoso , Biomarcadores/sangue , Feminino , França , Rejeição de Enxerto/sangue , Rejeição de Enxerto/diagnóstico , Humanos , Imunoglobulina G/sangue , Imunoglobulina G/classificação , Isoanticorpos/sangue , Isoanticorpos/classificação , Masculino , Pessoa de Meia-Idade , Valor Preditivo dos Testes , Estudos Prospectivos , Fatores de Risco , Índice de Gravidade de Doença , Resultado do Tratamento
2.
Cell Rep ; 30(8): 2581-2593.e7, 2020 02 25.
Artigo em Inglês | MEDLINE | ID: mdl-32101737

RESUMO

Neuronal Ca2+ entry elicited by electrical activity contributes to information coding via activation of K+ and Cl- channels. While Ca2+-dependent K+ channels have been extensively studied, the molecular identity and role of Ca2+-activated Cl- channels (CaCCs) remain unclear. Here, we demonstrate that TMEM16F governs a Ca2+-activated Cl- conductance in spinal motoneurons. We show that TMEM16F is expressed in synaptic clusters facing pre-synaptic cholinergic C-boutons in α-motoneurons of the spinal cord. Mice with targeted exon deletion in Tmem16f display decreased motor performance under high-demanding tasks attributable to an increase in the recruitment threshold of fast α-motoneurons. Remarkably, loss of TMEM16F function in a mouse model of amyotrophic lateral sclerosis (ALS) significantly reduces expression of an activity-dependent early stress marker and muscle denervation, delays disease onset, and preserves muscular strength only in male ALS mice. Thus, TMEM16F controls motoneuron excitability and impacts motor resistance as well as motor deterioration in ALS.


Assuntos
Esclerose Lateral Amiotrófica/patologia , Esclerose Lateral Amiotrófica/fisiopatologia , Anoctaminas/metabolismo , Atividade Motora , Neurônios Motores/metabolismo , Neurônios Motores/patologia , Proteínas de Transferência de Fosfolipídeos/metabolismo , Terminações Pré-Sinápticas/patologia , Medula Espinal/patologia , Animais , Biomarcadores/metabolismo , Canais de Cloreto/metabolismo , Colina/metabolismo , Progressão da Doença , Éxons/genética , Células HEK293 , Humanos , Masculino , Camundongos Endogâmicos C57BL , Condicionamento Físico Animal , Receptores Muscarínicos/metabolismo , Deleção de Sequência/genética
3.
Proc Natl Acad Sci U S A ; 116(6): 2312-2317, 2019 02 05.
Artigo em Inglês | MEDLINE | ID: mdl-30674678

RESUMO

Adaptive immune response is part of the dynamic changes that accompany motoneuron loss in amyotrophic lateral sclerosis (ALS). CD4+ T cells that regulate a protective immunity during the neurodegenerative process have received the most attention. CD8+ T cells are also observed in the spinal cord of patients and ALS mice although their contribution to the disease still remains elusive. Here, we found that activated CD8+ T lymphocytes infiltrate the central nervous system (CNS) of a mouse model of ALS at the symptomatic stage. Selective ablation of CD8+ T cells in mice expressing the ALS-associated superoxide dismutase-1 (SOD1)G93A mutant decreased spinal motoneuron loss. Using motoneuron-CD8+ T cell coculture systems, we found that mutant SOD1-expressing CD8+ T lymphocytes selectively kill motoneurons. This cytotoxicity activity requires the recognition of the peptide-MHC-I complex (where MHC-I represents major histocompatibility complex class I). Measurement of interaction strength by atomic force microscopy-based single-cell force spectroscopy demonstrated a specific MHC-I-dependent interaction between motoneuron and SOD1G93A CD8+ T cells. Activated mutant SOD1 CD8+ T cells produce interferon-γ, which elicits the expression of the MHC-I complex in motoneurons and exerts their cytotoxic function through Fas and granzyme pathways. In addition, analysis of the clonal diversity of CD8+ T cells in the periphery and CNS of ALS mice identified an antigen-restricted repertoire of their T cell receptor in the CNS. Our results suggest that self-directed immune response takes place during the course of the disease, contributing to the selective elimination of a subset of motoneurons in ALS.


Assuntos
Esclerose Lateral Amiotrófica/genética , Esclerose Lateral Amiotrófica/metabolismo , Expressão Gênica , Neurônios Motores/metabolismo , Mutação , Superóxido Dismutase-1/genética , Linfócitos T Citotóxicos/metabolismo , Esclerose Lateral Amiotrófica/diagnóstico , Esclerose Lateral Amiotrófica/fisiopatologia , Animais , Comunicação Celular/imunologia , Morte Celular , Sobrevivência Celular/genética , Modelos Animais de Doenças , Granzimas/metabolismo , Antígenos de Histocompatibilidade Classe I/imunologia , Ativação Linfocitária/imunologia , Camundongos , Camundongos Transgênicos , Neurônios Motores/imunologia , Fenótipo , Índice de Gravidade de Doença , Medula Espinal/citologia , Linfócitos T Citotóxicos/imunologia , Receptor fas/metabolismo
4.
Sci Rep ; 8(1): 5917, 2018 04 12.
Artigo em Inglês | MEDLINE | ID: mdl-29650983

RESUMO

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that affects the motor system leading to generalized paralysis and death of patients. The understanding of early pathogenic mechanisms will help to define early diagnostics criteria that will eventually provide basis for efficient therapeutics. Early symptoms of ALS usually include muscle weakness or stiffness. Therefore, mechanical response of differentiated myotubes from primary cultures of mice, expressing the ALS-causing SOD1 G93A mutation, was examined by atomic force microscopy. Simultaneous acquisition of topography and cell elasticity of ALS myotubes was performed by force mapping method, compared with healthy myotubes and supplemented with immunofluorescence and qRT-PCR studies. Wild type myotubes reveal a significant difference in elasticity between a narrow and a wide population, consistent with maturation occurring with higher actin expression relative to myosin together with larger myotube width. However, this is not true for SOD1 G93A expressing myotubes, where a significant shift of thin population towards higher elastic modulus values was observed. We provide evidence that SOD1 mutant induces structural changes that occurs very early in muscle development and well before symptomatic stage of the disease. These findings could significantly contribute to the understanding of the role of skeletal muscle in ALS pathogenesis.


Assuntos
Esclerose Lateral Amiotrófica/genética , Desenvolvimento Muscular/genética , Fibras Musculares Esqueléticas/química , Superóxido Dismutase-1/genética , Actinas/genética , Esclerose Lateral Amiotrófica/fisiopatologia , Animais , Diferenciação Celular/genética , Modelos Animais de Doenças , Elasticidade/fisiologia , Regulação da Expressão Gênica/efeitos dos fármacos , Humanos , Fenômenos Mecânicos , Camundongos , Microscopia de Força Atômica , Fibras Musculares Esqueléticas/patologia , Fibras Musculares Esqueléticas/ultraestrutura , Debilidade Muscular/genética , Mutação , Miosinas/genética , Superóxido Dismutase-1/química
5.
Neurobiol Dis ; 106: 35-48, 2017 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-28647557

RESUMO

Loss-of-function mutations in the potassium-chloride cotransporter KCC3 lead to Andermann syndrome, a severe sensorimotor neuropathy characterized by areflexia, amyotrophy and locomotor abnormalities. The molecular events responsible for axonal loss remain poorly understood. Here, we establish that global or neuron-specific KCC3 loss-of-function in mice leads to early neuromuscular junction (NMJ) abnormalities and muscular atrophy that are consistent with the pre-synaptic neurotransmission defects observed in patients. KCC3 depletion does not modify chloride handling, but promotes an abnormal electrical activity among primary motoneurons and mislocalization of Na+/K+-ATPase α1 in spinal cord motoneurons. Moreover, the activity-targeting drug carbamazepine restores Na+/K+-ATPase α1 localization and reduces NMJ denervation in Slc12a6-/- mice. We here propose that abnormal motoneuron electrical activity contributes to the peripheral neuropathy observed in Andermann syndrome.


Assuntos
Agenesia do Corpo Caloso/metabolismo , Neurônios Motores/metabolismo , Junção Neuromuscular/metabolismo , Doenças do Sistema Nervoso Periférico/metabolismo , Terminações Pré-Sinápticas/metabolismo , Simportadores/deficiência , Transmissão Sináptica/fisiologia , Agenesia do Corpo Caloso/tratamento farmacológico , Agenesia do Corpo Caloso/patologia , Animais , Carbamazepina/farmacologia , Células Cultivadas , Cloretos/metabolismo , Modelos Animais de Doenças , Camundongos Endogâmicos C57BL , Camundongos Transgênicos , Neurônios Motores/efeitos dos fármacos , Neurônios Motores/patologia , Junção Neuromuscular/efeitos dos fármacos , Junção Neuromuscular/patologia , Neurotransmissores/farmacologia , Doenças do Sistema Nervoso Periférico/tratamento farmacológico , Doenças do Sistema Nervoso Periférico/patologia , Terminações Pré-Sinápticas/efeitos dos fármacos , Terminações Pré-Sinápticas/patologia , ATPase Trocadora de Sódio-Potássio/metabolismo , Medula Espinal/efeitos dos fármacos , Medula Espinal/metabolismo , Medula Espinal/patologia , Simportadores/genética , Transmissão Sináptica/efeitos dos fármacos
6.
Hum Mol Genet ; 24(12): 3440-56, 2015 Jun 15.
Artigo em Inglês | MEDLINE | ID: mdl-25765661

RESUMO

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder that primarily affects motoneurons in the brain and spinal cord. Astrocyte and microglia activation as well as skeletal muscle atrophy are also typical hallmarks of the disease. However, the functional relationship between astrocytes, microglia and skeletal muscle in the pathogenic process remains unclear. Here, we report that the tumor necrosis factor-like weak inducer of apoptosis (Tweak) and its receptor Fn14 are aberrantly expressed in spinal astrocytes and skeletal muscle of SOD1(G93A) mice. We show that Tweak induces motoneuron death, stimulates astrocytic interleukin-6 release and astrocytic proliferation in vitro. The genetic ablation of Tweak in SOD1(G93A) mice significantly reduces astrocytosis, microgliosis and ameliorates skeletal muscle atrophy. The peripheral neutralization of Tweak through antagonistic anti-Tweak antibody ameliorates muscle pathology and notably, decreases microglial activation in SOD1(G93A) mice. Unexpectedly, none of these approaches improved motor function, lifespan and motoneuron survival. Our work emphasizes the multi-systemic aspect of ALS, and suggests that a combinatorial therapy targeting multiple cell types will be instrumental to halt the neurodegenerative process.


Assuntos
Esclerose Lateral Amiotrófica/genética , Esclerose Lateral Amiotrófica/patologia , Gliose/genética , Músculo Esquelético/metabolismo , Músculo Esquelético/patologia , Atrofia Muscular/genética , Fatores de Necrose Tumoral/genética , Esclerose Lateral Amiotrófica/metabolismo , Animais , Antígenos CD/metabolismo , Antígenos de Diferenciação Mielomonocítica/metabolismo , Astrócitos/metabolismo , Astrócitos/patologia , Morte Celular , Proliferação de Células , Citocina TWEAK , Modelos Animais de Doenças , Deleção de Genes , Regulação da Expressão Gênica , Interleucina-6/biossíntese , Expectativa de Vida , Camundongos , Camundongos Knockout , Camundongos Transgênicos , Microglia/metabolismo , Microglia/patologia , Placa Motora/genética , Placa Motora/metabolismo , Neurônios Motores/metabolismo , Neurônios Motores/patologia , Mutação , Receptores de Superfície Celular/metabolismo , Receptores do Fator de Necrose Tumoral/genética , Receptores do Fator de Necrose Tumoral/metabolismo , Transdução de Sinais , Medula Espinal/metabolismo , Superóxido Dismutase/genética , Superóxido Dismutase-1 , Receptor de TWEAK , Fatores de Necrose Tumoral/metabolismo , Regulação para Cima
7.
Mult Scler ; 20(13): 1699-703, 2014 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-24756568

RESUMO

BACKGROUND: auto-antibodies against the potassium channel inward rectifying potassium channel 4.1 (Kir4.1) have previously been identified in 46% of patients with multiple sclerosis (MS). OBJECTIVES: to confirm these findings. METHODS: we evaluated the presence of anti-Kir4.1 antibodies by enzyme-linked immunosorbent assay (ELISA) and immunofluorescence in 268 MS patients, 46 patients with other neurological diseases (OND) and 45 healthy controls. RESULTS: anti-Kir4.1 antibodies were found in 7.5% of MS patients, 4.3% of OND patients and 4.4% of healthy controls. Immunofluorescence analysis did not identify any specific staining. CONCLUSIONS: we confirmed the presence of anti-Kir4.1 antibodies in MS patients, but at a much lower prevalence than previously reported.


Assuntos
Autoanticorpos/sangue , Esclerose Múltipla/imunologia , Canais de Potássio Corretores do Fluxo de Internalização/imunologia , Adulto , Autoanticorpos/imunologia , Autoantígenos/imunologia , Biomarcadores/análise , Ensaio de Imunoadsorção Enzimática , Feminino , Imunofluorescência , Humanos , Masculino , Esclerose Múltipla/sangue
8.
EMBO Rep ; 15(5): 540-7, 2014 May.
Artigo em Inglês | MEDLINE | ID: mdl-24668263

RESUMO

A receptor-ligand interaction can evoke a broad range of biological activities in different cell types depending on receptor identity and cell type-specific post-receptor signaling intermediates. Here, we show that the TNF family member LIGHT, known to act as a death-triggering factor in motoneurons through LT-ßR, can also promote axon outgrowth and branching in motoneurons through the same receptor. LIGHT-induced axonal elongation and branching require ERK and caspase-9 pathways. This distinct response involves a compartment-specific activation of LIGHT signals, with somatic activation-inducing death, while axonal stimulation promotes axon elongation and branching in motoneurons. Following peripheral nerve damage, LIGHT increases at the lesion site through expression by invading B lymphocytes, and genetic deletion of Light significantly delays functional recovery. We propose that a central and peripheral activation of the LIGHT pathway elicits different functional responses in motoneurons.


Assuntos
Axônios/fisiologia , Neurônios Motores/metabolismo , Membro 14 da Superfamília de Ligantes de Fatores de Necrose Tumoral/genética , Membro 14 da Superfamília de Ligantes de Fatores de Necrose Tumoral/metabolismo , Animais , Linfócitos B/imunologia , Butadienos/farmacologia , Caspase 9/metabolismo , Inibidores de Caspase/farmacologia , Proliferação de Células , MAP Quinases Reguladas por Sinal Extracelular/antagonistas & inibidores , MAP Quinases Reguladas por Sinal Extracelular/metabolismo , Flavonoides/farmacologia , Receptor beta de Linfotoxina/antagonistas & inibidores , Receptor beta de Linfotoxina/metabolismo , Camundongos , Camundongos Knockout , Nitrilas/farmacologia , Inibidores de Proteínas Quinases/farmacologia , Proteínas Recombinantes/genética , Proteínas Recombinantes/farmacologia , Nervo Isquiático/lesões , Nervo Isquiático/patologia , Membro 14 da Superfamília de Ligantes de Fatores de Necrose Tumoral/biossíntese
9.
Neurobiol Aging ; 35(5): 1198-205, 2014 May.
Artigo em Inglês | MEDLINE | ID: mdl-24378089

RESUMO

Amyotrophic lateral sclerosis (ALS) is an incurable paralytic disorder primarily typified by the selective and progressive degeneration of motoneurons in the brain and spinal cord. ALS causes muscle wasting and atrophy, resulting eventually in respiratory failure and death within 3-5 years of diagnosis. Vitamin D is a potent secosteroid hormone with diverse biological functions that include protection against neuronal damage. The detrimental consequences of vitamin D dietary deficiency have been documented in other neurodegenerative diseases. However, the protective effect of vitamin D on motoneuron and the influence of its levels on disease course remains elusive. Here we found that the biologically active form of vitamin D significantly potentiated the effect of neurotrophic factors and prevented motoneurons from a Fas-induced death, while electrophysiological properties of motoneurons were not affected. In ALS patients, we report that a severe vitamin D deficiency accelerates by 4 times the rate of decline and were associated with a marked shorter life expectancy. Our findings support a neuroprotective function of vitamin D on motoneurons and propose vitamin D as a reliable prognostic factor of ALS.


Assuntos
Esclerose Lateral Amiotrófica/tratamento farmacológico , Sobrevivência Celular/efeitos dos fármacos , Neurônios Motores/efeitos dos fármacos , Fármacos Neuroprotetores , Vitamina D/farmacologia , Esclerose Lateral Amiotrófica/mortalidade , Esclerose Lateral Amiotrófica/patologia , Animais , Células Cultivadas , Proteína Ligante Fas/fisiologia , Feminino , Fator Neurotrófico Derivado de Linhagem de Célula Glial/farmacologia , Humanos , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Pessoa de Meia-Idade , Neuritos/fisiologia , Taxa de Sobrevida , Fatores de Tempo , Vitamina D/administração & dosagem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA